cota-logo-wht-rgb
Contact Us
cota-logo-wht-rgb

Research matters

When you’re focusing on the future of cancer care, it helps to start with a clear and accurate picture of the present.

Abstract
May 31, 2023
MORE →
Abstract
May 31, 2023
MORE →
Breast Cancer
April 4, 2023
MORE →

Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets

Brittany Avin McKelvey, Elizabeth Garrett-Mayer, Andrew J. Belli, Thomas D. Brown, Jessica Dow, Janet L. Espirito, Paul Kluetz, Xinran Ma, Andrea McCracken, Pallavi Shruti Mishra-Kalyani, Yanina Natanzon, Danielle Potter, Donna Rivera, Hillary Stires, Mark Stewart, Jeff Allen
Friends of Cancer Research formed a multi-stakeholder partnership to assess available data attributes to measure response across RWD sources to inform development of a consistent method for measurement.
  • ASCO, Friends of Cancer Research, NSCLC
ABSTRACT

Real-world (RW) treatment (tx) patterns of patients (pts) with higher-risk myelodysplastic syndrome (MDS) in a US RWE database (COTA).

Rami S. Komrokji, Leyla Hernandez Donoso, Sejla Hodzic, Henry F Owusu, Kevin Nolan, Claire Nourry, Maria Diez-Campelo
Pts with higher-risk MDS have poor outcomes. To understand current tx patterns/identify unmet needs, the COTA database, using pt-level curated electronic health record (EHR) data from centers across the US, was analyzed.
  • ASCO, Myelodysplastic Syndromes
ABSTRACT

An indirect comparison of elranatamab’s (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM)

Luciano J. Costa, Thomas William LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Marco DiBonaventura
A retrospective cohort study was conducted to indirectly compare the efficacy observed in MM-3 Cohort A (BCMA-naïve; N=123) from the 9-month data cut with two US-based oncology electronic health record databases, Flatiron Health (FH) and COTA, as external controls.
  • ASCO, External Control, Multiple Myeloma
ABSTRACT

Racial and ethnic representation in large B-cell lymphoma trials and real-world databases.

Javier Munoz, Alex Mutebi, Tongsheng Wang, Guihua Zhang, Junhua Yu, Jing He, Anindit Chibber, Rajesh Kamalakar, Monika P. Jun, Kelechi Adejumo, Shibing Yang, Anupama Kalsekar
In large B-cell lymphoma (LBCL) trials, racial and ethnic representation is difficult to determine due to underreporting in some regions, or because some patients may not provide data. Analyses of the distribution of different racial and ethnic categories were conducted across 6 real-world clinical practice databases from the United States (US): SEER-Medicare, COTA, Medicare, Optum Market Clarity, Optum CDM, and ConcertAI RWD.
  • ASCO, Lymphoma
ABSTRACT

Outcomes among Hispanic metastatic breast cancer patients treated with alpelisib and fulvestrant: Single institution retrospective study.

Yolcar Chamorro, Reshma L. Mahtani, Shanada Monestime, Naomi Dempsey, Mukesh Roy, Muni B. Rubens, Manmeet Singh Ahluwalia, Ana Cristina Sandoval-Leon
A retrospective chart review was performed to include pts with HR+ HER2- MBC with a documented PIK3CA mutation (detected by ctDNA or tissue) treated with alpelisib in combination with fulvestrant at Miami Cancer Institute from 2019-2022. Pts were identified using pharmacy records and the COTA real-world database (RWD).
  • ASCO, Breast Cancer
ABSTRACT

The COTA Nodal Address Model: A Novel Digital Classification System Identifies Variances in Cancer Care Cost to Support Value Based Care Delivery

Andrew L. Pecora MD, Andrew Ip MD MS, Ching-Kun Wang MD, Stuart L. Goldberg MD, Andre H. Goy MD, Lili Brillstein, MPH, CEO, Glenn Pomerantz MD JD, Michael B. Atkins MD, and Donald M. Berwick MD
We have previously described a digital classification schema (Cota Nodal Address [CNA]) which incorporates validated prognostic elements. We propose to demonstrate that reducing variation in cancer care among similar patients might lead to decreased costs without affecting clinical benefit. Identifying variation is difficult under claims-based coding systems (i.e. ICD-10) that group cancer subtypes. We aim to use the CNA model to investigate variations in care.
  • Cota Nodal Address (CNA) Development and Validation
ABSTRACT

Abstract 967: Real-world transcriptomic biomarkers as replacement for immunohistochemistry and FISH studies in breast cancer

Maher Albitar, Andre Goy, Andrew Pecora, Deena Graham, Donna Donna McNamara, Ahmad Ahmad Charifa, Andrew IP, Wanlong Ma, Stanley Waintraub
Human epidermal growth factor receptor-2 (HER2) and hormone receptors are typically used as binary biomarkers for selecting breast cancer therapy. There is a need to explore the clinical relevance of these biomarkers as continuous variables. This is particularly relevant for the new class of antibody-drug conjugates (ADC), in which a relatively low HER2 expression level is adequate for targeting tumor cells. We explored the potential of RNA profiling, determined by next generation sequencing (NGS), to provide more flexible clinical biomarkers as compared with immunohistochemistry (IHC) or fluorescent in situ hybridization (FISH).
  • Breast Cancer, Outcomes Research
ABSTRACT

HSR23-106: Real-World Study of Disease-Free Survival and Associated Patient Characteristics in Early-Stage Non–Small Cell Lung Cancer (NSCLC): A Retrospective Observational Study

Anne Shah PhD, Jon Apple PharmD, Andrew J. Belli MPH, Anna Barcellos MPH, Eric Hansen MS, Laura L. Fernandes PhD, and Ching-Kun Wang MD
Surgical resection is the primary treatment with curative intent for early-stage NSCLC; however, many patients experience recurrence even after resection. The goal for this study was to assess the real-world disease-free survival (rwDFS) and patient characteristics, including epidermal growth factor receptor mutation (EGFRm) status, associated with rwDFS in stages IB-IIIA NSCLC patients.
  • Lung Cancer, Outcomes Research
ABSTRACT

Bringing clarity to cancer

We are working to ensure that everyone touched by cancer has a clear path to the right care.

Privacy Policy

Terms of Use

CCPA Privacy Notice

Subscribe for Updates

Receive our latest news and research from thought leaders in the RWD industry
  • This field is for validation purposes and should be left unchanged.